SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors

被引:8
|
作者
Qu, D. [1 ]
Yan, A. [1 ]
Zhang, J. S. [2 ]
机构
[1] Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Beijing, Peoples R China
[2] Renmin Univ China, High Sch, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Human epidermal growth factor receptor-2 (HER2) inhibitor; structure-activity relationship (SAR); quantitative structure-activity relationship (QSAR); support vector machine (SVM); random forest (RF); multiple linear regression (MLR); ORALLY-ACTIVE INHIBITORS; NEUTRAL; 5-SUBSTITUTED; 4-ANILINOQUINAZOLINES; PYRROLOTRIAZINE DUAL INHIBITORS; TYROSINE KINASE INHIBITORS; BIOLOGICAL EVALUATION; IRREVERSIBLE INHIBITORS; ERBB RECEPTORS; MULTITARGETED INHIBITORS; PYRAZOLINE DERIVATIVES; MOLECULAR DOCKING;
D O I
10.1080/1062936X.2017.1284898
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this paper, structure-activity relationship (SAR, classification) and quantitative structure-activity relationship (QSAR) models have been established to predict the bioactivity of human epidermal growth factor receptor-2 (HER2) inhibitors. For the SAR study, we established six SAR (or classification) models to distinguish highly and weakly active HER2 inhibitors. The dataset contained 868 HER2 inhibitors, which was split into a training set including 580 inhibitors and a test set including 288 inhibitors by a Kohonen's self-organizing map (SOM), or a random method. The SAR models were performed using support vector machine (SVM), random forest (RF) and multilayer perceptron (MLP) methods. Among the six models, SVM models obtained superior results compared with other models. The prediction accuracy of the best model (model 1A) was 90.27% and the Matthews correlation coefficient (MCC) was 0.80 on the test set. For the QSAR study, we chose 286 HER2 inhibitors to establish six quantitative prediction models using MLR, SVM and MLP methods. The correlation coefficient (r) of the best model (model 4B) was 0.92 on the test set. The descriptors analysis showed that HAccN, lone pair electronegativity and electronegativity were closely related to the bioactivity of HER2 inhibitors.
引用
收藏
页码:111 / 132
页数:22
相关论文
共 50 条
  • [31] Human epidermal growth factor receptor-2 in oesophageal cancers:An observational study
    Hazem Al-Momani
    Rachel Barnes
    Ahmed El-Hadi
    Rachit Shah
    Wyn G Lewis
    Paul Edwards
    World Journal of Gastroenterology, 2012, (44) : 6447 - 6451
  • [32] A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors
    Xu, YM
    Wang, LF
    Jia, LT
    Qiu, XC
    Zhao, J
    Yu, CJ
    Zhang, R
    Zhu, F
    Wang, CJ
    Jin, BQ
    Chen, SY
    Yang, AG
    JOURNAL OF IMMUNOLOGY, 2004, 173 (01): : 61 - 67
  • [33] Quantitative Measurement of Human Epidermal Growth Factor Receptor-2 ( HER2) Protein Expression in 'Classical' and 'Non-Classical' FISH Categories: a Comparative Study
    Shen, Jian
    Buscaglia, Brandon
    Goda, Hideki
    Turner, Bradley M.
    Okada, Hisatake
    Mcmahon, Loralee
    Henry, Jill
    Nakano, Yasushi
    Hicks, David
    LABORATORY INVESTIGATION, 2018, 98 : 105 - 105
  • [34] Quantitative Measurement of Human Epidermal Growth Factor Receptor-2 (HER2) Protein Expression in 'Classical' and 'Non-Classical' FISH Categories: a Comparative Study
    Shen, Jian
    Buscaglia, Brandon
    Goda, Hideki
    Turner, Bradley M.
    Okada, Hisatake
    Mcmahon, Loralee
    Henry, Jill
    Nakano, Yasushi
    Hicks, David
    MODERN PATHOLOGY, 2018, 31 : 105 - 105
  • [35] Human epidermal growth factor receptor-2 in oesophageal cancers: An observational study
    Al-Momani, Hazem
    Barnes, Rachel
    El-Hadi, Ahmed
    Shah, Rachit
    Lewis, Wyn G.
    Edwards, Paul
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (44) : 6447 - 6451
  • [36] Dual targeting of human epidermal growth factor receptor 2 (HER2) in neoadjuvant trials for operable HER2 positive (HER2+) disease
    Jhaveri K.
    Dang C.
    Current Breast Cancer Reports, 2013, 5 (4) : 321 - 330
  • [37] Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity
    Mahboobi, Siavosh
    Sellmer, Andreas
    Winkler, Matthias
    Eichhorn, Emerich
    Pongratz, Herwig
    Ciossek, Thomas
    Baer, Thomas
    Maier, Thomas
    Beckers, Thomas
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (24) : 8546 - 8555
  • [38] Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario
    Earle, Craig
    Ferrusi, Ilia L.
    Trudeau, Maureen E.
    Leighl, Natasha B.
    Pullenayegum, Eleanor
    Khong, Hoa
    Hoch, Jeffrey
    Marshall, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
  • [39] Circulating human epidermal growth factor receptor 2 (HER2) is associated with hyperglycaemia and insulin resistance
    Memon, Ashfaque A.
    Bennet, Louise
    Zoller, Bengt
    Wang, Xiao
    Palmer, Karolina
    Sundquist, Kristina
    Sundquist, Jan
    JOURNAL OF DIABETES, 2015, 7 (03) : 369 - 377
  • [40] Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies
    Schrohl, Anne-Sofie
    Pedersen, Hans Christian
    Jensen, Sussie Steen
    Nielsen, Signe Lykke
    Bruenner, Nils
    HISTOPATHOLOGY, 2011, 59 (05) : 975 - 983